Gilead Sciences Revenue 2010-2022 | GILD
Gilead Sciences annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Gilead Sciences revenue for the quarter ending September 30, 2022 was $7.042B, a 5.11% decline year-over-year.
- Gilead Sciences revenue for the twelve months ending September 30, 2022 was $27.136B, a 1.26% decline year-over-year.
- Gilead Sciences annual revenue for 2021 was $27.305B, a 10.6% increase from 2020.
- Gilead Sciences annual revenue for 2020 was $24.689B, a 9.98% increase from 2019.
- Gilead Sciences annual revenue for 2019 was $22.449B, a 1.46% increase from 2018.
Gilead Sciences Annual Revenue
(Millions of US $) |
| 2021 |
$27,305 |
| 2020 |
$24,689 |
| 2019 |
$22,449 |
| 2018 |
$22,127 |
| 2017 |
$26,107 |
| 2016 |
$30,390 |
| 2015 |
$32,639 |
| 2014 |
$24,890 |
| 2013 |
$11,202 |
| 2012 |
$9,702 |
| 2011 |
$8,385 |
| 2010 |
$7,949 |
| 2009 |
$7,011 |
Gilead Sciences Quarterly Revenue
(Millions of US $) |
| 2022-09-30 |
$7,042 |
| 2022-06-30 |
$6,260 |
| 2022-03-31 |
$6,590 |
| 2021-12-31 |
$7,244 |
| 2021-09-30 |
$7,421 |
| 2021-06-30 |
$6,217 |
| 2021-03-31 |
$6,423 |
| 2020-12-31 |
$7,421 |
| 2020-09-30 |
$6,577 |
| 2020-06-30 |
$5,143 |
| 2020-03-31 |
$5,548 |
| 2019-12-31 |
$5,879 |
| 2019-09-30 |
$5,604 |
| 2019-06-30 |
$5,685 |
| 2019-03-31 |
$5,281 |
| 2018-12-31 |
$5,795 |
| 2018-09-30 |
$5,596 |
| 2018-06-30 |
$5,648 |
| 2018-03-31 |
$5,088 |
| 2017-12-31 |
$5,949 |
| 2017-09-30 |
$6,512 |
| 2017-06-30 |
$7,141 |
| 2017-03-31 |
$6,505 |
| 2016-12-31 |
$7,320 |
| 2016-09-30 |
$7,500 |
| 2016-06-30 |
$7,776 |
| 2016-03-31 |
$7,794 |
| 2015-12-31 |
$8,506 |
| 2015-09-30 |
$8,295 |
| 2015-06-30 |
$8,244 |
| 2015-03-31 |
$7,594 |
| 2014-12-31 |
$7,314 |
| 2014-09-30 |
$6,042 |
| 2014-06-30 |
$6,535 |
| 2014-03-31 |
$4,999 |
| 2013-12-31 |
$3,120 |
| 2013-09-30 |
$2,783 |
| 2013-06-30 |
$2,767 |
| 2013-03-31 |
$2,532 |
| 2012-12-31 |
$2,588 |
| 2012-09-30 |
$2,427 |
| 2012-06-30 |
$2,405 |
| 2012-03-31 |
$2,282 |
| 2011-12-31 |
$2,200 |
| 2011-09-30 |
$2,122 |
| 2011-06-30 |
$2,137 |
| 2011-03-31 |
$1,926 |
| 2010-12-31 |
$1,999 |
| 2010-09-30 |
$1,938 |
| 2010-06-30 |
$1,927 |
| 2010-03-31 |
$2,086 |
| 2009-12-31 |
$2,032 |
| 2009-09-30 |
$1,801 |
| 2009-06-30 |
$1,647 |
| 2009-03-31 |
$1,530 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$105.984B |
$27.281B |
|
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
|
